CervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies

MT Newswires Live06-18

CervoMed (CRVO) received a notice of allowance from the US Patent and Trademark Office related to a patent application for the use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies, the company said Thursday.

The patent is expected to cover the treatment of dementia with Lewy bodies without substantial Alzheimer's disease-like tau pathology and is expected to provide intellectual property protection into 2042, with the potential for additional patent term extension, CervoMed said.

CervoMed said there are currently no approved treatments for dementia with Lewy bodies in the United States or the European Union.

Shares of CervoMed were up more than 5% in Thursday pre-bell activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644088933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644088933","market":"sh","top_or_hot":-1,"title":"CervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> (CRVO) received a notice of allowance from the US Patent and Trademark Office related to a patent application for the use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies, the company said Thursday.</p><p>The patent is expected to cover the treatment of dementia with Lewy bodies without substantial Alzheimer's disease-like tau pathology and is expected to provide intellectual property protection into 2042, with the potential for additional patent term extension, CervoMed said.</p><p>CervoMed said there are currently no approved treatments for dementia with Lewy bodies in the United States or the European Union.</p><p>Shares of CervoMed were up more than 5% in Thursday pre-bell activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> (CRVO) received a notice of allowance from the US Patent and Trademark Office related to a patent application for the use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies, the company said Thursday.</p><p>The patent is expected to cover the treatment of dementia with Lewy bodies without substantial Alzheimer's disease-like tau pathology and is expected to provide intellectual property protection into 2042, with the potential for additional patent term extension, CervoMed said.</p><p>CervoMed said there are currently no approved treatments for dementia with Lewy bodies in the United States or the European Union.</p><p>Shares of CervoMed were up more than 5% in Thursday pre-bell activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644088933","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644088933","pubTimestamp":1781782573,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CervoMed  received a notice of allowance from the US Patent and Trademark Office related to a patent application for the use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies, the company said Thursday.The patent is expected to cover the treatment of dementia with Lewy bodies without substantial Alzheimer's disease-like tau pathology and is expected to provide intellectual property protection into 2042, with the potential for additional patent term extension, CervoMed said.CervoMed said there are currently no approved treatments for dementia with Lewy bodies in the United States or the European Union.Shares of CervoMed were up more than 5% in Thursday pre-bell activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"CervoMed收到Neflamapimod治疗路易体痴呆专利许可通知","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":1.5},"content_text":"CervoMed (CRVO) received a notice of allowance from the US Patent and Trademark Office related to a patent application for the use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies, the company said Thursday.The patent is expected to cover the treatment of dementia with Lewy bodies without substantial Alzheimer's disease-like tau pathology and is expected to provide intellectual property protection into 2042, with the potential for additional patent term extension, CervoMed said.CervoMed said there are currently no approved treatments for dementia with Lewy bodies in the United States or the European Union.Shares of CervoMed were up more than 5% in Thursday pre-bell activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644088933","isCrawlerRequest":true}